Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA-1 TCR-transduced virus-specific donor T cells after allogeneic stem cell transplantation for high-risk leukemia
NL-OMON26148Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2012
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HA-1 TCR-transduced virus-specific donor-derived T cells in leukemia, sponsored by Leiden University Medical Center. Primary endpoints: Safety and Feasibility of cell product generation. Planned start Jun 2012; status: not yet recruiting.
02
Drugs
HA-1 TCR-transduced virus-specific donor-derived T cells
03
Conditions
leukemia
Beyond the preview
Go deeper on NL-OMON26148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26148.